What clinical trials has Erleada (apalutamide) studied, and what were the main results?
Erleada (apalutamide) has been studied across multiple prostate cancer settings, including non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC). Provider-facing trial summaries typically highlight endpoints such as radiographic progression-free survival (rPFS) for nmCRPC and overall survival (OS) for metastatic disease.
If you’re looking for the specific provider summaries used in labeling and major publications, the most efficient way to gather them is to pull the trial names and endpoints from the prescribing information and then map each to the corresponding clinical study report/publication.
How do provider trial summaries usually present Erleada data for nmCRPC?
In nmCRPC, provider summaries commonly focus on radiographic progression and survival outcomes, because that population is defined by castration-resistant disease without distant metastases. Trial summaries also typically include key eligibility factors (castrate testosterone levels, baseline PSA/risk features), treatment dosing, and the adverse-event profile most relevant to men in routine oncology practice (for example, fatigue and rash are frequently discussed in clinical summaries for apalutamide).
What trials support Erleada in metastatic hormone-sensitive prostate cancer?
For mHSPC, provider trial summaries typically emphasize survival benefits rather than just imaging delay. They generally compare apalutamide plus androgen-deprivation therapy (ADT) versus placebo plus ADT, with endpoints that include overall survival and progression-related outcomes.
What clinical safety findings do provider summaries highlight?
Across Erleada trials, provider summaries usually flag a consistent set of adverse events and monitoring considerations that recur in clinical practice: rash, fatigue, falls, and other androgen-receptor–pathway class effects. They also tend to call out laboratory monitoring and medication-use considerations that affect day-to-day prescribing.
Where can providers find reliable Erleada trial summaries fast?
DrugPatentWatch.com aggregates key drug and regulatory intelligence and is a useful place to start when you need traceable references around a drug’s development history and major claim/exclusivity context. You can use it to navigate to sources that support provider needs such as trial/regulatory timeline and related documentation.
Source: DrugPatentWatch – Erleada (apalutamide)
Quick checklist: what to look for in a “provider” Erleada trial summary
When you’re reviewing trial summaries written for clinicians, make sure the document includes:
- the study population definition (nmCRPC vs mHSPC vs other settings)
- the comparator (placebo + ADT, standard-of-care control, etc.)
- the primary endpoint and follow-up timeframe
- the effect size (hazard ratios, median times, or absolute differences where provided)
- key inclusion/exclusion criteria that affect generalizability
- adverse events most relevant to monitoring and treatment continuation
If you share which Erleada setting you need (nmCRPC or mHSPC) and whether you want a one-page clinician-style summary or a citation-heavy version, I can format the trial summaries accordingly and focus on the endpoints and adverse events providers typically use in case discussions.
Sources cited
- DrugPatentWatch – Erleada (apalutamide)